Your Trusted Source for Canadian News and Insights

Social

Your Trusted Source for Canadian News and Insights
HomeSocial

All News

Elcogen Applauded by Frost & Sullivan for Enabling High-efficiency, Emission-free Power and Green Hydrogen Production with Its Versatile Solid Oxide Fuel Cell and Stack Technologies

Elcogen\'s advanced SOFC and SOEC technologies provide scalable,cost-effective solutions for both residential and industrial applications that enable high efficiency,fuel flexibility,and lower emissi

Jan 15, 2025
Social

ITALY, SIGEP WORLD, THE GLOBAL FOODSERVICE COMMUNITY'S LEADING SHOW, IS ABOUT TO START: 1,300 BRANDS

Trends,innovation,technologies and now also pizza at Italian Exhibition Group\'s 46th edition featuring sustainable sector initiatives in the name of internationality,at Rimini Expo Centre from 18th

Jan 15, 2025
Social

Timekettle CEO Leal Tian Joins Elite Panel on AI Innovation at Microsoft's Event During CES 2025

LAS VEGAS,Jan. 14,2025-- During CES 2025,Microsoft Greater China held a specialized event themed "Be AI Ready,Win Globally," focusing on empowering Chinese enterprises that are expanding in

Jan 15, 2025
Social

AM Green and DP World Join Forces to Establish India as a Global Hub for Green Molecules

Aiming to export 2 MTPA of green fuels,this partnership positions India as a leader in global decarbonization efforts.

Jan 15, 2025
Social

Korea's Leading Indie Beauty Brand d'Alba, Reaches New Heights Globally with 210% Overseas Sales Surge

SEOUL,South Korea,Jan. 14,2025-- Premium vegan beauty brandd\'Alba has achieved significant growth in its overseas sales,rising to approximately KRW 150 billion won (USD 100 million) in 2024 - which i

Jan 15, 2025
Social

ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS

SEOUL,South Korea,Jan. 14,2025-- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for \'Pemziviptadil (development code name PF1804),\' a treatment for DMD (Duch

Jan 15, 2025
Social
1 ... 64 65 66 67 68 69 70 ... 72